ARTICLE | Distillery Therapeutics
Therapeutics: c-jun N-terminal kinase 2 (JNK2; MAPK9); JNK3 (MAPK10)
February 19, 2015 8:00 AM UTC
In vitro studies have identified aminopyrazole-based JNK2/3-selective inhibitors that could help treat neurodegenerative diseases linked to neuronal oxidative stress. In vitro, the lead compound inhib...